Qiyuan Pharmaceutical Obtains Customs AEO Advanced Enterprise Certification

On December 12, 2022, Qiyuan Pharmaceutical was awarded the AEO Advanced Certified Enterprise Certificate by Yinchuan Customs.

In early 2021, following preliminary consultations with Yinchuan Customs and an internal comparative assessment, Qiyuan Pharmaceutical decided to launch its AEO Advanced Certification project. This decision was made in strict accordance with the requirements of the "Measures of the Customs of the People's Republic of China for the Credit Management of Enterprises Registered or Recorded with the Customs" and the “Standards for Advanced Certified Enterprises”. Consequently, the company established a dedicated Customs Certification Team, led by the Marketing Department and comprising personnel from the Procurement, Administration, Microcomputer Management, Production Safety, and Finance Departments, as well as the Quality and Technology Center and Workshop 307. Working against the certification standards, the team conducted detailed inspections; revised and refined certification system documentation and records; rectified information system hardware and software; and comprehensively advanced all work related to the AEO Advanced Certification.

On November 14, 2022, Qiyuan Pharmaceutical submitted its final application materials. A panel of Customs certification experts subsequently conducted a rigorous review of Qiyuan Pharmaceutical's internal controls, financial health, compliance standards, and trade security measures through on-site inspections, document reviews, and Q&A sessions. Ultimately, Qiyuan Pharmaceutical was approved for AEO Advanced Certification status.

The Customs AEO Advanced Certification represents the highest credit rating for international trading enterprises—a status mutually recognized by customs authorities worldwide. It requires enterprises to demonstrate a robust management system, sound financial indicators, and comprehensive cargo security management protocols. By obtaining this certification, enterprises gain access to a range of customs facilitation measures—such as the lowest inspection rates, exemptions from guarantees, and priority customs clearance—thereby further reducing operational costs. The acquisition of this "Green Pass" for global trade undoubtedly injects new momentum into Qiyuan Pharmaceutical's continued efforts to deepen its presence in the international market.